AT-M10 Normal-iI2
ATLABi012-A
General
Cell Line |
|
hPSCreg name | ATLABi012-A |
Cite as: | ATLABi012-A |
Alternative name(s) |
AT-M10 Normal-iI2
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
ATLABi013-A (AT-M10 Normal-iII3) |
Last update | 30th September 2021 |
User feedback | |
Provider |
|
Generator |
IMCB, Adrian Teo's Lab (ATLAB)
Contact:
IMCB, Adrian Teo's Lab (ATLAB) |
Owner | IMCB, Adrian Teo's Lab (ATLAB) |
Distributors | |
Derivation country | Singapore |
External Databases |
|
BioSamples | SAMEA9726681 |
General Information |
|
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
Sex | female |
Age of donor (at collection) | 65-69 |
Ethnicity | Asian Chinese |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
46, XX
Karyotyping method:
G-Banding
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
All cell lines of this donor's relatives |
Has son:
Has daughter:
Has son:
|
External Databases (Donor) |
|
BioSamples | SAMEA10202006 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Please provide contact information of the holder of the original Donor Information Sheet. | ateo@imcb.a-star.edu.sg |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | Yes |
Please provide the contact information | Dr. Adrian Teo : ateo@imcb.a-star.edu.sg |
Alternatives to consent are available? | No |
Confirm that consent was obtained by a qualified professional | Yes |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | CIRB |
Approval number | 2015/2003 |
Do you have obligations to third parties in regard to the use of the cell line? | Yes |
Please describe: | In consultation with clinician collaborator |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type | |
Age of donor (at collection) | 65-69 |
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Episomal |
Vector free reprogramming |
|
Type of used vector free reprogramming factor(s) |
None
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Feeder cells |
Irradiated CF-1 mouse embryonic fibroblasts |
|||||||||||||||
Passage method | Mechanically | |||||||||||||||
CO2 Concentration | 5 % | |||||||||||||||
Medium |
Other medium:
Base medium: DMEM/F-12
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
|||||||||||||||
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Unknown |
|||||||||||||||
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
|||||||||||||||
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Unknown |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
POU5F1 (OCT-4) |
Yes |
|||||
SOX2 |
Yes |
|||||
NANOG |
Yes |
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
46, XX
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.